CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-11 | Woiwode Thomas Director | Other acquisition | +9,719 | 9,719 | ||
| 2021-06-11 | Woiwode Thomas Director | Other disposition | −9,719 | 0 | ||
| 2021-06-11 | Woiwode Thomas Director | Other acquisition | +8,383 | 8,383 | ||
| 2021-06-11 | Woiwode Thomas Director | Other disposition | −8,383 | 0 | ||
| 2021-06-11 | Woiwode Thomas Director | Other acquisition | +2,226 | 4,452 | ||
| 2021-04-26 | Woiwode Thomas Director | Other disposition | −485,979 | 1,943,916 | ||
| 2021-04-26 | Woiwode Thomas Director | Other acquisition | +9,720 | 9,720 | ||
| 2021-04-26 | Woiwode Thomas Director | Other disposition | −9,720 | 0 | ||
| 2021-04-26 | Woiwode Thomas Director | Other acquisition | +8,385 | 8,385 | ||
| 2021-04-26 | Woiwode Thomas Director | Other disposition | −8,385 | 0 | ||
| 2021-04-26 | Woiwode Thomas Director | Other acquisition | +2,226 | 2,226 | ||
| 2021-04-26 | Scopa James Paul Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2020-12-01 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2020-12-01 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +176,237 | 176,237 | ||
| 2020-12-01 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2020-12-01 | Beigelman Leonid President | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2020-12-01 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2020-10-20 | Novo Holdings A/S 10% owner | Conversion | +2,414,563 | 2,414,563 | ||
| 2020-10-20 | Novo Holdings A/S 10% owner | Purchase | +200,000 | $15.00 | $3.0M | 2,614,563 |
| 2020-10-20 | Novo Holdings A/S 10% owner | Conversion · SERIES A CONVERTIBLE PREFERRED STOCK | −1,609,493 | 0 |
Page 7 of 12 · 238 trades